We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Envista (NVST) Up 0.8% Since Last Earnings Report: Can It Continue?
Read MoreHide Full Article
It has been about a month since the last earnings report for Envista (NVST - Free Report) . Shares have added about 0.8% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Envista due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Envista Tops Q2 Earnings and Revenues
Envista Holdings Corporation reported adjusted earnings per share of 41 cents in the second quarter of 2026, up 57.7% year over year. The bottom line surpassed the Zacks Consensus Estimate by 24.24%.
The adjustments include non-cash charges related to the amortization of acquisition-related and other intangible assets, restructuring costs and asset impairments, fair-value adjustment of acquisition-related inventory and tariff refunds, among others.
The company’s GAAP earnings were 33 cents compared with the year-ago quarter’s earnings of 16 cents per share.
NVST’s Revenues
Revenues totaled $730.5 million in the reported quarter, up 7.1% year over year. The metric topped the Zacks Consensus Estimate by 2.17%.
Segment-wise, Specialty Products & Technologies sales totaled $471 million, up 5.8% year over year. Revenues from Equipment & Consumables rose 9.5% year over year to $259.5 million in the quarter under review.
NVST’s Operational Update
The gross profit in the reported quarter climbed 10% year over year to $407 million. The gross margin expanded 149 basis points (bps) to 55.7% despite cost of sales increasing 3.6%.
Selling, general and administrative expenses were up 0.3% year over year to $296.3 million. Research and development expenses rose 7.4% year over year to $30.4 million. The operating profit of $80.3 million jumped 73.4% year over year. The operating margin expanded 420 bps to 11%.
NVST’s Financial Update
Envista ended the second quarter of 2026 with cash and cash equivalents of $1.13 billion compared with $1.08 billion as of Apr. 3. Long-term debt in the second quarter was $1.44 billion compared with $1.43 billion at the end of first quarter. Cumulative net cash provided by operating activities as of July 3, 2026 was $115.9 million compared with $89 million a year ago.
Envista’s 2026 Guidance
For 2026, the company expects core sales growth between 3.5% and 4.5% (previously, 2%-4%). The Zacks Consensus Estimate projects 2026 sales to be $2.88 billion, representing 6% growth over 2025.
Adjusted EBITDA growth is projected in the range of 11%-14%, previously 7%-13%.
Adjusted diluted earnings per share are projected between $1.50 and $1.55 (earlier, $1.35 to $1.45). The consensus mark for the metric stands at $1.53.
Free cash flow conversion is expected to be approximately 100%.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a upward trend in estimates review.
VGM Scores
At this time, Envista has a subpar Growth Score of D, a score with the same score on the momentum front. However, the stock has a grade of B on the value side, putting it in the second quintile for value investors.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Envista has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry Player
Envista belongs to the Zacks Medical - Products industry. Another stock from the same industry, Neogen (NEOG - Free Report) , has gained 3% over the past month. More than a month has passed since the company reported results for the quarter ended May 2026.
Neogen reported revenues of $225.3 million in the last reported quarter, representing a year-over-year change of -0.1%. EPS of $0.09 for the same period compares with $0.05 a year ago.
For the current quarter, Neogen is expected to post earnings of $0.05 per share, indicating a change of +25% from the year-ago quarter. The Zacks Consensus Estimate has changed +4.4% over the last 30 days.
Neogen has a Zacks Rank #2 (Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.
View the Zacks #1 Rank List
Image: Bigstock
Envista (NVST) Up 0.8% Since Last Earnings Report: Can It Continue?
It has been about a month since the last earnings report for Envista (NVST - Free Report) . Shares have added about 0.8% in that time frame, outperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Envista due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Envista Tops Q2 Earnings and Revenues
Envista Holdings Corporation reported adjusted earnings per share of 41 cents in the second quarter of 2026, up 57.7% year over year. The bottom line surpassed the Zacks Consensus Estimate by 24.24%.
The adjustments include non-cash charges related to the amortization of acquisition-related and other intangible assets, restructuring costs and asset impairments, fair-value adjustment of acquisition-related inventory and tariff refunds, among others.
The company’s GAAP earnings were 33 cents compared with the year-ago quarter’s earnings of 16 cents per share.
NVST’s Revenues
Revenues totaled $730.5 million in the reported quarter, up 7.1% year over year. The metric topped the Zacks Consensus Estimate by 2.17%.
Segment-wise, Specialty Products & Technologies sales totaled $471 million, up 5.8% year over year. Revenues from Equipment & Consumables rose 9.5% year over year to $259.5 million in the quarter under review.
NVST’s Operational Update
The gross profit in the reported quarter climbed 10% year over year to $407 million. The gross margin expanded 149 basis points (bps) to 55.7% despite cost of sales increasing 3.6%.
Selling, general and administrative expenses were up 0.3% year over year to $296.3 million. Research and development expenses rose 7.4% year over year to $30.4 million. The operating profit of $80.3 million jumped 73.4% year over year. The operating margin expanded 420 bps to 11%.
NVST’s Financial Update
Envista ended the second quarter of 2026 with cash and cash equivalents of $1.13 billion compared with $1.08 billion as of Apr. 3. Long-term debt in the second quarter was $1.44 billion compared with $1.43 billion at the end of first quarter. Cumulative net cash provided by operating activities as of July 3, 2026 was $115.9 million compared with $89 million a year ago.
Envista’s 2026 Guidance
For 2026, the company expects core sales growth between 3.5% and 4.5% (previously, 2%-4%). The Zacks Consensus Estimate projects 2026 sales to be $2.88 billion, representing 6% growth over 2025.
Adjusted EBITDA growth is projected in the range of 11%-14%, previously 7%-13%.
Adjusted diluted earnings per share are projected between $1.50 and $1.55 (earlier, $1.35 to $1.45). The consensus mark for the metric stands at $1.53.
Free cash flow conversion is expected to be approximately 100%.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed a upward trend in estimates review.
VGM Scores
At this time, Envista has a subpar Growth Score of D, a score with the same score on the momentum front. However, the stock has a grade of B on the value side, putting it in the second quintile for value investors.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been trending upward for the stock, and the magnitude of these revisions looks promising. It comes with little surprise Envista has a Zacks Rank #1 (Strong Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry Player
Envista belongs to the Zacks Medical - Products industry. Another stock from the same industry, Neogen (NEOG - Free Report) , has gained 3% over the past month. More than a month has passed since the company reported results for the quarter ended May 2026.
Neogen reported revenues of $225.3 million in the last reported quarter, representing a year-over-year change of -0.1%. EPS of $0.09 for the same period compares with $0.05 a year ago.
For the current quarter, Neogen is expected to post earnings of $0.05 per share, indicating a change of +25% from the year-ago quarter. The Zacks Consensus Estimate has changed +4.4% over the last 30 days.
Neogen has a Zacks Rank #2 (Buy) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.